Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427191 · ClinicalTrials.gov registry record · Phase 2
Micronized dHACM Injectable for the Treatment of Plantar Fasciitis
A Phase 2 study of Fasciitis, Plantar, sponsored by MiMedx Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 11
- Study locations
NCT02427191: Completed Phase 2 study of Fasciitis, Plantar, sponsored by MiMedx Group.
NCT02427191 is a Phase 2 study of Fasciitis, Plantar that has completed, run by MiMedx Group. The registered enrollment target is 147 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02427191, a Phase 2 study of Fasciitis, Plantar, has completed, sponsored by MiMedx Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 11
- Study locations
Study Summary
Prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
Primary Outcome
Visual Analog Scale
Conditions Studied
Interventions
- DRUG Saline Injection
- OTHER AmnioFix® Injectable
Study Locations (11)
California
- Limb Preservation Platform, Inc. - Fresno
- Center for Clinical Research, Inc. - San Francisco
Illinois
- Edward Hines Jr. Veterans Administration Hospital - Chicago
- James A. Lovell Federal Health Care Center - North Chicago
Maryland
- Timonium Foot and Ankle Center - Baltimore
- MedStar Union Memorial Hospital - Baltimore
Arizona
- Southern Arizona VA Health Care System - Tucson
Florida
- Orlando VA Healthcare System - Orlando
South Carolina
- WJB Dorn VA Medical Center - Columbia
Texas
- Scott & White Healthcare - Temple
Virginia
- Coastal Podiatry Group - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT02427191 record still lists
NCT02427191 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Fasciitis, Plantar appearing as the primary indexed condition, and to 2 interventions - of which Saline Injection is the first listed.
NCT02427191 lists 11 locations in 8 states (California, Illinois, Maryland).
Frequently Asked Questions
What is clinical trial NCT02427191 about?
NCT02427191 is a clinical study titled "Micronized dHACM Injectable for the Treatment of Plantar Fasciitis". Prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
What is the current status of trial NCT02427191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2015-03-31. Estimated completion is 2018-08.
What conditions does trial NCT02427191 study?
This clinical trial studies the following conditions: Fasciitis, Plantar.
What interventions are being tested in trial NCT02427191?
The interventions under investigation include: Saline Injection (DRUG), AmnioFix® Injectable (OTHER).
Who is sponsoring clinical trial NCT02427191?
This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02427191 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02427191's enrollment target sits among peer trials
147 495th of 2000 higher than 1,505 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI